Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes

被引：48

作者：

Fujishima, Yuya ^{[1
]}

Maeda, Norikazu ^{[1
]}

Inoue, Kana ^{[1
]}

Kashine, Susumu ^{[1
]}

Nishizawa, Hitoshi ^{[1
]}

Hirata, Ayumu ^{[1
]}

Kozawa, Junji ^{[1
]}

Yasuda, Tetsuyuki ^{[1
]}

Okita, Kohei ^{[1
]}

Imagawa, Akihisa ^{[1
]}

Funahashi, Tohru ^{[1
]}

Shimomura, Iichiro ^{[1
]}

机构：

[1] Osaka Univ, Grad Sch Med, Dept Metab Med, Suita, Osaka 5650871, Japan

来源：

CARDIOVASCULAR DIABETOLOGY | 2012年 / 11卷

关键词：

Liraglutide; Glucagon-like peptide-1 (GLP-1); Obesity; Eating behavior; Diabetes; Incretin; CARDIOVASCULAR RISK-FACTORS; BLOOD-GLUCOSE IMPROVES; FOOD-INTAKE; NORMALIZATION; HYPOGLYCEMIA; DISEASE; SAFETY;

D O I：

10.1186/1475-2840-11-107

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Background: We recently reported that short-term treatment with liraglutide (20.0 +/- 6.4 days) reduced body weight and improved some scales of eating behavior in Japanese type 2 diabetes inpatients. However, it remained uncertain whether such liraglutide-induced improvement is maintained after discharge from the hospital. The aim of the present study was to determine the long-term effects of liraglutide on body weight, glycemic control, and eating behavior in Japanese obese type 2 diabetics. Methods: Patients with obesity (body mass index (BMI) >25 kg/m(2)) and type 2 diabetes were hospitalized at Osaka University Hospital between November 2010 and December 2011. BMI and glycated hemoglobin (HbA1c) were examined on admission, at discharge and at 1, 3, and 6 months after discharge. For the liraglutide group (BMI; 31.3 +/- 5.3 kg/m(2), n = 29), patients were introduced to liraglutide after correction of hyperglycemic by insulin or oral glucose-lowering drugs and maintained on liraglutide after discharge. Eating behavior was assessed in patients treated with liraglutide using The Guideline For Obesity questionnaire issued by the Japan Society for the Study of Obesity, at admission, discharge, 3 and 6 months after discharge. For the insulin group (BMI; 29.1 +/- 3.0 kg/m(2), n = 28), each patient was treated with insulin during hospitalization and glycemic control maintained by insulin after discharge. Results: Liraglutide induced significant and persistent weight loss from admission up to 6 months after discharge, while no change in body weight after discharge was noted in the insulin group. Liraglutide produced significant improvements in all major scores of eating behavior questionnaire items and such effect was maintained at 6 months after discharge. Weight loss correlated significantly with the decrease in scores for recognition of weight and constitution, sense of hunger, and eating style. Conclusion: Liraglutide produced meaningful long-term weight loss and significantly improved eating behavior in obese Japanese patients with type 2 diabetes.

引用

页数：8

共 24 条

[1] The Extrapancreatic Effects of Glucagon-Like Peptide-1 and Related Peptides [J].